Patricia Delaite

Nessuna posizione attualmente

61 anni

Health Technology

Consumer Services

Profilo

Patricia Delaite served as an Independent Director at Cantargia AB from 2017 to 2023.
Prior to that, she held the position of Chief Medical Officer at Amal Therapeutics SA and Nouscom AG.
Dr. Delaite holds a doctorate degree from the University of Geneva and an MBA from the University of Lausanne.

Precedenti posizioni note di Patricia Delaite

Società	Posizione	Fine
CANTARGIA AB	Direttore/Membro del Consiglio	23/05/2023
Nouscom AG Nouscom AG Pharmaceuticals: MajorHealth Technology Nouscom AG engages in the development of genetic neoantigen vaccines and oncolytic viruses for prevention and treatment of cancer. Its product pipeline include Nous-209, Nous-PEV, and Nous-THV-001. The company was founded by Alfredo Nicosia, Antonella Folgori, Riccardo Cortese, Stefano Colloca, Cinzia Traboni, Elisa Scarselli, and Gabriella Campadelli in 2007 and is headquartered in Basel, Switzerland.	Direttore Tecnico/Scientifico/R&S	-
Amal Therapeutics SA Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland.	Direttore Tecnico/Scientifico/R&S	-

Vedi nel dettaglio l'esperienza di Patricia Delaite

Formazione di Patricia Delaite

University of Geneva	Doctorate Degree
University of Lausanne	Masters Business Admin

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Patricia Delaite

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
CANTARGIA AB	Health Technology

Aziende private	2
Amal Therapeutics SA Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland.	Health Technology
Nouscom AG Nouscom AG Pharmaceuticals: MajorHealth Technology Nouscom AG engages in the development of genetic neoantigen vaccines and oncolytic viruses for prevention and treatment of cancer. Its product pipeline include Nous-209, Nous-PEV, and Nous-THV-001. The company was founded by Alfredo Nicosia, Antonella Folgori, Riccardo Cortese, Stefano Colloca, Cinzia Traboni, Elisa Scarselli, and Gabriella Campadelli in 2007 and is headquartered in Basel, Switzerland.	Health Technology